This clinical trial is focused on studying the long-term effects of a treatment for Chronic Hepatitis B, a liver infection caused by the hepatitis B virus. The treatment being evaluated is called bepirovirsen, which is administered as a solution for injection. This study is designed to observe how well the treatment response lasts over time in participants who have previously been treated with bepirovirsen, with or without additional nucleos(t)ide therapy, which is another type of medication used to manage hepatitis B.

The purpose of the study is to understand the durability of the treatment response. Participants in this study will have their health monitored over a period of time to see how their condition progresses after receiving bepirovirsen. The study will involve regular check-ups to assess the levels of certain markers in the blood that indicate the presence of the hepatitis B virus and the body’s response to the treatment. These markers include HBsAg, which is a protein on the surface of the hepatitis B virus, and HBV DNA, which is the genetic material of the virus.

Throughout the study, researchers will also look for any signs of the virus returning or any need for additional medication. The study aims to provide valuable information on how effective bepirovirsen is in maintaining a long-term response in people with chronic hepatitis B, helping to improve future treatment strategies for this condition.